Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a tailored Stop-Smoking program help cancer patients quit?

NCT ID NCT04694846

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested an enhanced tobacco intervention program (ETIP) for people with head and neck or lung cancer who smoke. The program combined counseling, nicotine replacement, and medications like bupropion or varenicline. Nineteen participants were enrolled to see if the program could reduce smoking by at least half. The goal was to help patients quit smoking to potentially improve their cancer treatment outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nicotine replacement therapy, bupropion, and varenicline
What this could lead to
If successful, this approach could help cancer patients quit smoking, potentially improving treatment outcomes and reducing cancer progression.
What could go wrong
This was a small feasibility study with only 19 participants, so results may not apply broadly. The intervention may not lead to long-term abstinence or affect tumor biology.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

19 people

The number who actually took part.

Started

Aug 2020

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provide signed written informed consent document * New patients opting to receive cancer care at Thomas Jefferson University Hospital (TJUH) or Methodist with suspected or newly diagnosed head and neck squamous cell carcinoma (HNSCC) or non-small cell carcinoma of the lung * Must have a life expectancy of at least 6 months as judged by the treating physician * Willing to discuss changing their smoking behavior * Patients have smoked \> 100 cigarettes in their lifetime and have smoked within the last 30 days * Subjects must read and speak fluent English Exclusion Criteria: * Patients with psychiatric disorders with indications of current uncontrolled illness, or patients currently being treated on psychiatric medications * Patients with expected survival of less than 6 months or other medical illness that would prevent participation as determined by the treating clinician * Patients not fluent in English will be excluded, as the counselling component of the intervention is only available in English * Pregnant or breastfeeding women * Severe swallowing disorders or other illness that would impede a patient's ability to swallow medications in pill form * Patients with impaired judgement or those unable to provide informed consent * Contraindications to nicotine replacement therapy: * All free flap patients: Nicotine replacement therapy (NRT) and tobacco products must not be used by these patients for at least 2 weeks before and 2 weeks after free flap surgery. For planned procedures involving face and breast, tobacco and NRT use should be avoided 4 weeks before and 4 weeks after surgery * Patients in the immediate (within 2 weeks) post myocardial infarction period or who have serious arrhythmias or unstable angina pectoris * Patient who are hemodynamically or electrically unstable or have had orthopedic surgery or a serious fracture(s) within the past 6 weeks * Patients with known allergy or hypersensitivity to NRT, or severe skin reactions like Steven's Johnson syndrome * Contraindications to bupropion or varenicline: * Pre-existing seizure disorder or conditions that increase the risk of seizures (e.g., severe head trauma, arteriovenous malformation, central nervous system (CNS) tumor (e.g., brain tumor or intracranial mass), CNS infection, severe stroke, anorexia nervosa, bulimia nervosa * Patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs * Concomitant use of anti-depressants * Patients with known allergy or hypersensitivity to bupropion or varenicline, or severe skin reactions like Steven's Johnson syndrome

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck squamous cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Jefferson Health, Methodist Hospital

    Philadelphia, Pennsylvania, 19148, United States

  • Sidney Kimmel Cancer Center at Thomas Jefferson Univeristy

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.